HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Changchun High-Tech Industry / Equity Capital Markets

<ul>
<li>CHANGCHUN HIGH-TECH’s stock price has been declining for more than four years since the news broke in May 2021 that growth hormone was to be included in 17-province VBP alliance.</li>
<li>GenSci’s innovative drug pipeline layout does have some ideas, but in fact, there are no expected blockbuster products among them - Their technological barriers and long-term exclusivity are relatively limited.</li>
<li>Short-Term performance pain is inevitable due to negative growth of main business and strategic transformation. The market may give it a conservative valuation, which may be lower than peers.</li>
</ul>


CHANGCHUN HIGH-TECH’s stock price has been declining for more than four years since the news broke in May 2021 that growth hormone was to be included in 17-province VBP alliance.
GenSci’s innovative drug pipeline layout does have some ideas, but in fact, there are no expected blockbuster products among them - Their technological barriers and long-term exclusivity are relatively limited.
Short-Term performance pain is inevitable due to negative growth of main business and strategic transformation. The market may give it a conservative valuation, which may be lower than peers.


Pre-IPO Changchun High-Tech Industry (A/H Listing) - The Business and the Outlook

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

<ul>
<li>There have been 14 new listings on the Main Board of the <a href="https://www.smartkarma.com/entities/hong-kong-exchanges-clearing" target="_blank" data-smartkarma-citation="entities:490:1" rel="noopener">HKEX</a> in Q1. One listing is a transfer from the GEM Board and one is a De-SPAC.</li>
<li>Of the 14 stocks, we see <a href="https://www.smartkarma.com/entities/mixue-group" target="_blank" data-smartkarma-citation="entities:40623:1" rel="noopener">Mixue Group (2097 HK)</a>, <a href="https://www.smartkarma.com/entities/guming-holdings-limited" target="_blank" data-smartkarma-citation="entities:40622:1" rel="noopener">Guming Holdings (1364 HK)</a> and <a href="https://www.smartkarma.com/entities/bloks-group" target="_blank" data-smartkarma-citation="entities:43648:1" rel="noopener">Bloks Group (1850960D CH)</a> as potential HSCI inclusions in June.</li>
<li>There are no lock-up expiries in the stocks ahead of inclusion in Southbound Stock Connect and the low float could take the stocks higher ahead of the index inclusion announcement.</li>
</ul>


There have been 14 new listings on the Main Board of the HKEX in Q1. One listing is a transfer from the GEM Board and one is a De-SPAC.
Of the 14 stocks, we see Mixue Group (2097 HK), Guming Holdings (1364 HK) and Bloks Group (1850960D CH) as potential HSCI inclusions in June.
There are no lock-up expiries in the stocks ahead of inclusion in Southbound Stock Connect and the low float could take the stocks higher ahead of the index inclusion announcement.


HSCI Index Rebalance Preview: Three Hot Inclusions to Stock Connect in June

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

JX Advanced Metals / Equity Capital Markets

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, <a href="https://www.smartkarma.com/entities/jx-advanced-metals-corporation" target="_blank" data-smartkarma-citation="entities:44346:1" rel="noopener">JX Advanced Metals (5016 JP)</a> managed to hold on to its deal price, riding on the copper price resurgance.</li>
<li>On the placements front, <a href="https://www.smartkarma.com/entities/judo-capital" target="_blank" data-smartkarma-citation="entities:34571:1" rel="noopener">Judo Capital (JDO AU)</a> was the only largish deal over the past week.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, JX Advanced Metals (5016 JP) managed to hold on to its deal price, riding on the copper price resurgance.
On the placements front, Judo Capital (JDO AU) was the only largish deal over the past week.


ECM Weekly (24th Mar 2025) -JX Advance, DN Solutions, Nanshan Aluminimum, Anthem, EAAA, Judo Capital

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

VISEN Pharmaceuticals / Equity Capital Markets

<ul>
<li>Visen Pharmaceuticals is looking at raising up to USD 100m to list in Hong Kong.</li>
<li>In an apparently downsized deal, the company is trying to sell at a blue sky valuation.</li>
<li>We disagree with its valuation and noted that tones have turned bearish in its offering documents.</li>
</ul>


Visen Pharmaceuticals is looking at raising up to USD 100m to list in Hong Kong.
In an apparently downsized deal, the company is trying to sell at a blue sky valuation.
We disagree with its valuation and noted that tones have turned bearish in its offering documents.


Pharmaceuticals (维升药业) IPO: Valuation and Book Building

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, <a href="https://www.smartkarma.com/entities/mixue-group" target="_blank" data-smartkarma-citation="entities:40623:1" rel="noopener">Mixue Group (2097 HK)</a> looks set to break the tea chain jinx in its listing today, while <a href="https://www.smartkarma.com/entities/jx-advanced-metals-corporation" target="_blank" data-smartkarma-citation="entities:44346:1" rel="noopener">JX Advanced Metals (5016 JP)</a> will set its pricing.</li>
<li>On the placements front, <a href="https://www.smartkarma.com/entities/japan-post-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:359:1" rel="noopener">Japan Post Holdings (6178 JP)</a> was back with a US$4bn+ deal in <a href="https://www.smartkarma.com/entities/japan-post-bank-co-ltd" target="_blank" data-smartkarma-citation="entities:838:1" rel="noopener">Japan Post Bank (7182 JP)</a>.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, Mixue Group (2097 HK) looks set to break the tea chain jinx in its listing today, while JX Advanced Metals (5016 JP) will set its pricing.
On the placements front, Japan Post Holdings (6178 JP) was back with a US$4bn+ deal in Japan Post Bank (7182 JP).


ECM Weekly (3rd Mar 2025) - Japan Post Bank, JX Advance, Mixue, Chifeng, JSW Cement, Premier, Guzman

China

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on endocrine diseases. It develops and commercializes therapies for conditions such as pediatric growth hormone deficiency, achondroplasia, and chronic hypoparathyroidism. The company was founded in 2018 and is headquartered in Suzhou, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

VISEN Pharmaceuticals (2561 HK)

Pre-IPO Changchun High-Tech Industry (A/H Listing) - The Business and the Outlook

CHANGCHUN HIGH-TECH INDUSTRY is under pressure due to negative growth of main business and is in strategic transformation.The market may give it a...

Xinyao (Criss) Wang

HSCI Index Rebalance Preview: Three Hot Inclusions to Stock Connect in June

There could be 3 adds to the HSCI and Southbound Stock Connect in June. There are no lock-up expiries in the stocks prior to June and the low float...

Brian Freitas

ECM Weekly (24th Mar 2025) -JX Advance, DN Solutions, Nanshan Aluminimum, Anthem, EAAA, Judo Capital

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Pharmaceuticals (维升药业) IPO: Valuation and Book Building

Visen Pharmaceuticals seeks to raise $100m for Hong Kong listing. We think the valuation is extremely inflated with tones turning bearing in the...

Ke Yan, CFA, FRM

ECM Weekly (3rd Mar 2025) - Japan Post Bank, JX Advance, Mixue, Chifeng, JSW Cement, Premier, Guzman

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO Changchun High-Tech Industry (A/H Listing) - The Business and the Outlook

CHANGCHUN HIGH-TECH INDUSTRY is under pressure due to negative growth of main business and is in strategic transformation.The market may give it a...

Xinyao (Criss) Wang

HSCI Index Rebalance Preview: Three Hot Inclusions to Stock Connect in June

There could be 3 adds to the HSCI and Southbound Stock Connect in June. There are no lock-up expiries in the stocks prior to June and the low float...

Brian Freitas

ECM Weekly (24th Mar 2025) -JX Advance, DN Solutions, Nanshan Aluminimum, Anthem, EAAA, Judo Capital

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Pharmaceuticals (维升药业) IPO: Valuation and Book Building

​Visen Pharmaceuticals seeks to raise $100m for Hong Kong listing. We think the valuation is extremely inflated with tones turning bearing in the...

Ke Yan, CFA, FRM

ECM Weekly (3rd Mar 2025) - Japan Post Bank, JX Advance, Mixue, Chifeng, JSW Cement, Premier, Guzman

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Visen Pharmaceuticals seeks to raise $100m for Hong Kong listing. We think the valuation is extremely inflated with tones turning bearing in the...